IL-UNITAS-GLOBAL
22.2.2021 14:03:13 CET | Business Wire | Press release
Unitas Global announces the availability of Unitas Reach™ , the first global software defined network (SDN) to offer automated ubiquitous edge access to any cloud location. Enterprises are finding that current networks are a bottleneck to the adoption of new technologies and capabilities – these problems have not been resolved, until now. Unitas Reach™ is the industry's first purpose-built network connecting cloud providers, carrier-neutral data centers, SaaS applications, and edge access networks to form a multi-service global interconnection fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005156/en/
"Organizations today need flexible, proven, and secure infrastructure to run their enterprise applications and multi-cloud solutions," shares Patrick Shutt, CEO of Unitas Global. "With Unitas Reach™, our clients achieve cost-optimized network connectivity with the agility needed to scale quickly and support the growing demands of applications on network architectures, performance, and costs."
Unitas Reach™ is built to provide connectivity options that different modern cloud services require with simple integration to traditional enterprise networks. With its presence on six continents, Unitas Reach™ provides redundant and diverse Internet, IP, Ethernet, and Wave access to distributed applications across any cloud, hybrid-cloud, multi-cloud, or private cloud destination. Strategic interconnections with hundreds of other networks and fiber access providers further extends the network access to the edge, including over 900 carrier neutral data centers and 30 million enterprise locations in over 85 countries. Sophisticated automation, monitoring, and orchestration to the edge make the entire interconnect fabric unmatched in enabling complete flexibility in service creation and scaling capacity as enterprise networking needs change.
"We designed Unitas Reach™ in response to the dynamic networking requirements that today's businesses require and have yet to experience," comments Grant Kirkwood, Founder and CTO of Unitas Global. "Providers and enterprises can easily add connectivity to dynamically support their ever changing network strategies, and customize capabilities to their unique set of service delivery, operations, access and configuration requirements.”
Unitas' edge to everywhere connectivity solutions offer providers and enterprises with automated:
- Cloud On-ramps™ for multi-cloud delivery
- High performance managed Internet
- Direct connectivity to and between multi-cloud platforms
- Agile and scalable WAN solutions
Unitas Reach™ provides the greatest choice and ease of use for provisioning enterprises with connectivity that delivers agile, cost-effective, low-latency connections to optimize application performance. Unitas Global solves the enterprise challenge by going to market with MSPs, hyperscalers, and data centers who are able to establish an on-net point of presence with Unitas Reach™ to expand their network coverage, scale services everywhere, and locate applications as close to customers as possible to improve performance and optimize costs.
Learn more about Unitas Reach™ and its edge to everywhere connectivity solution.
About Unitas Global
Unitas Global is a global managed network service provider offering automated ubiquitous edge access to any cloud, everywhere. The company provides the most agile connected multi-cloud environments that are easy-to-consume, fully managed, and backed by a promise to deliver the best application performance. Connect with Unitas at LinkedIn , Twitter , and its Blog .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom